---
title: treatment of chronic myelogenous leukemia (CML)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[chronic myelogenous leukemia (CML)]]


# treatment of chronic myelogenous leukemia (CML)Â 

(LancetÂ 2015;385:1447;Â Hematol Oncol Clin North Am2017;31:577)

[[hypomethylating agents|HMA]]: azacitidine or decitabine

## Tyrosine kinase inhibitors (TKI)

> âŒ abl kinase activity.

---

![ğŸ”](https://i.imgur.com/JAWSrLm.png)

---

* 1stÂ gen:
	* [[imatinib]], 1stÂ TKI againstÂ [[BCR-ABL1]]Â (NEJMÂ 2017;376:917)
	* 400mg daily may 800mg

* 2ndÂ gen:
	* [[nilotinib]],  [[dasatinib]],  bosutinib.
	* consider if high [[Sokal score]], â†‘ response but â†‘ toxicity.
	* No survival difference.

* 3rdÂ gen:
	* [[ponatinib]];
	* a/w â†“ risk of disease progress of treatment of chronic myelogenous leukemia (CML)
	* preferred for int-high risk,
	* but â†‘ toxicity

---

* Imatinib, dasatinib, nilotinib, & bosutinib approved for 1stÂ line Rx.
* Nilotinib, dasatinib, bosutinib, ponatinib, & asciminib approved for resistant disease;
* only ponatinib & asciminib effective on T315I mutationÂ (NEJMÂ 2012;367:2075,Â BloodÂ 2021;138:2031).

---

* STAMP (allosteric inhibitor): asciminibÂ (NEJMÂ 2019;381:2315); after â‰¥2 prior TKIs

* Resistance: due to â†‘Â BCR-ABL1Â expression, often 2/2Â ABLÂ kinase mutation or amplification

* [[Side effects of tyrosine kinase inhibitor]]

* [[TKI discontinuation]]:

* Consider allogeneic HSCT for AP and BP.

* CML in pregnancy: hydroxyurea & all TKIs contraind. If Rx needed, IFN (only option).

* [[Milestones of Therapy of treatment of chronic myelogenous leukemia (CML)]]

